Creative Medical Technology Holdings: Initiating Coverage With A Sell Rating

2025-05-12 15:59:35 ET

Summary

• Initiating coverage on Creative Medical Technology Holdings with a Sell rating due to early-stage pipeline and significant downside risks outweighing potential upside.
• The company’s pipeline includes AlloStem for diabetes, AlloStemSpine for back pain, and OvaStem for infertility, all in early development with high uncertainty.
• Financially, Creative Medical has limited cash reserves, high cash burn, and will likely need dilutive financing, posing significant risks to current shareholders.
• Competing therapies from larger companies in diabetes and back pain markets could overshadow Creative Medical’s offerings, making commercial success uncertain.

Introduction

We are initiating coverage on Creative Medical Technology Holdings ( CELZ ) with a Sell rating. Creative Medical is a small clinical-stage biotech focusing on cell therapies for diabetes, immune disorders, orthopedic and gynecologic diseases. The company has a pipeline of regenerative medicine products, but all are in early development stages with significant uncertainty and are targeting markets with intense competition, in our opinion. ...

Read the full article on Seeking Alpha

For further details see: